Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Support Care Cancer. 2001 Mar;9(2):84-96.

Hydromorphone: pharmacology and clinical applications in cancer patients.

Author information

  • 1Harry R. Horvitz Center for Palliative Medicine, Taussig Cancer Center of Cleveland Clinic Foundation, Cleveland, Ohio, USA.

Abstract

Hydromorphone is a more potent opioid analgesic than morphine and is used for moderate to severe pain. It can be administered by injection, by infusion, by mouth, and rectally. Oral bioavailability is low. The kidney excretes hydromorphone and its metabolites. Some metabolites may have greater analgesic activity than hydromorphone itself but are unlikely to contribute to the pharmacological activity of hydromorphone. With the exception of pruritus, sedation and nausea and vomiting, which may occur less after hydromorphone than after morphine, the side-effects of these drugs are similar. On a milligram basis hydromorphone is five times as potent as morphine when given by the oral route, and 8.5 times as potent as morphine when given intravenously.

PMID:
11305075
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk